This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
January 29, 2021
Orexo expects FDA filing of OX124 mid 2022
January 28, 2021
Orexo Q4 2020, incl. Full Year Report
January 27, 2021
Orexo strengthens IP rights for overdose rescue drug OX124
January 19, 2021
InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation
January 13, 2021
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®
January 07, 2021
CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies
January 06, 2021
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
January 06, 2021
Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
January 06, 2021
Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore
January 05, 2021
Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines